知镜 Cognispect · 医学文献与研究工作台

First-line pemigatinib in a myeloid/lymphoid neoplasm with FGFR1 rearrangement: shifting the current treatment paradigm.

Stafylidis C, Variami E, Lakiotaki E, Patsialos I, Syriopoulou S, Sideris K, Kontandreopoulou CN, Vlachopoulou D, Stouggioti S, Solomou E, Plaka M, Georgakopoulos N, Korkolopoulou P, Mantzourani M, Diamantopoulos P.
Leukemia & lymphoma · 2026-11-02 · PMID 42972525

文献摘要

Myeloid/lymphoid neoplasms with FGFR1 rearrangement (MLN FGFR1 ) are rare, aggressive hematologic malignancies with limited treatment options. Although pemigatinib is approved for relapsed/refractory disease, evidence supporting its role in the frontline setting remains limited. We report a 69-year-old female with newly diagnosed MLN FGFR1 in blast phase, presenting with concurrent myeloproliferative neoplasm and T-lymphoblastic lymphoma. As the patient declined intensive chemotherapy, frontline pemigatinib was initiated in combination with intrathecal chemotherapy for central nervous system prophylaxis. A rapid hematologic response was achieved, followed by complete metabolic and cytogenetic responses. At 17 months after pemigatinib initiation, she remains in complete remission, with treatment-related toxicity being manageable through dose modifications and temporary interruptions. This case illustrates the potential of FGFR1 inhibition as a frontline therapeutic option in selected patients with MLN FGFR1 , while highlighting the importance of careful toxicity management and the need for further studies to establish its role in this setting.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。